Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Docetaxel-Epirubicin Plus Bevacizumab in Metastatic HER2- Breast Cancer
NCT00705315Phase 2Completed
- Sponsor
- Hellenic Oncology Research Group
- Start
- May 2008
- Primary completion
- Jun 2010
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of bevacizumab in breast cancer, sponsored by Hellenic Oncology Research Group. Primary endpoint: Overall Response Rate at Cycle 6. Started May 2008; status: completed.
02
Drugs
bevacizumab
03
Conditions
breast cancer
Beyond the preview
Go deeper on NCT00705315.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00705315.